FDA's New Stance on Drug Pricing: Impact on Approvals and Pharma Strategy

FDA's New Stance on Drug Pricing: Impact on Approvals and Pharma Strategy

The FDA is taking a more active role in drug pricing, potentially influencing approval timelines and market access. This shift presents both opportunities and challenges for pharmaceutical companies, requiring strategic adaptation. For BD teams and investors, the central question is no longer whether the agency will intervene — but how deeply pricing considerations will reshape the approval process and competitive dynamics across therapeutic areas.

Key Takeaways: FDA's Evolving Role in Drug Pricing

• FDA's direct involvement in pricing introduces new regulatory use — companies that cooperate on pricing may gain accelerated approvals and more favorable review interactions.
• Non-compliance with administration pricing demands could trigger regulatory delays, increased scrutiny of submissions, and even modification or revocation of existing approvals.
• This represents a significant departure from the FDA's traditional science-only mandate, creating a new variable in drug development and commercialization strategies that BD teams must now model into deal-making.
• The approach blurs the historically clear boundary between FDA and CMS, introducing uncertainty that investors should factor into pipeline valuations and regulatory risk assessments.

What Happened: FDA Moves Directly Into Drug Pricing

In the first year of the second Trump administration, the Food and Drug Administration stepped into territory it had long avoided. A May 15, 2025, executive order on most-favored-nation (MFN) prescription drug pricing directed the FDA to "review and potentially modify or revoke approvals granted for drugs" if manufacturers refused to explore MFN pricing strategies. Published in the Federal Register, the order signaled that the administration intended to use the agency's approval authority as a lever on list prices.

Historically, the FDA had suggested pricing might be considered a condition for obtaining or maintaining approval — but had never directly tied its regulatory authority to the price of the drugs it reviews. Drug pricing and coverage were left to the Centers for Medicare and Medicaid Services or private insurance plans. The May 2025 order broke that convention.

FDA Commissioner Marty Makary subsequently signaled the agency's willingness to act on the executive order, and agency actions over the second half of 2025 clarified that the FDA intended to play a role in the administration's broader pricing strategy. As Skadden, Arps, Slate, Meagher & Flom noted in a January 2026 sector spotlight, the agency's interest in influencing drug prices marks "a dramatic shift for a regulator that has prided itself on only carrying out its science-backed public health mission." The firm warned that companies refusing price cuts could face regulatory delays, obstacles, and reputational damage.

How Should Pharma BD and Regulatory Teams Respond?

The practical consequences for pharmaceutical companies are immediate and multifaceted. Business development teams must now factor pricing posture into partnership and licensing negotiations. A company that has publicly committed to MFN pricing alignment may find itself in a stronger position when submitting an NDA or BLA — and BD leaders should weigh that regulatory advantage when evaluating acquisition targets or co-development partners.

Regulatory affairs teams face a more complex submission environment. Pricing considerations need to be integrated into regulatory strategy from Phase III planning onward, not bolted on after approval. Companies may need to develop parallel workstreams: one tracking the standard clinical and CMC requirements, another monitoring administration pricing signals and preparing responsive positions. The cost of getting this wrong is tangible — a delayed review or a public pricing dispute with the FDA can compress launch windows and hand first-mover advantages to competitors.

Investors should watch for signals in FDA advisory committee minutes, Federal Register notices, and commissioner public remarks. Companies that proactively engage with the FDA on pricing — without undermining their commercial positioning — may secure smoother regulatory pathways. Those that resist publicly risk not only delays but negative headlines that can weigh on stock performance. The Skadden analysis emphasized that the agency's willingness to take "bold action" means pricing non-compliance is now a material regulatory risk, not a theoretical concern.

For global companies, the divergence between FDA and EMA mandates adds another layer of complexity. The European Medicines Agency's marketing authorization framework remains focused on safety, efficacy, and quality — with pricing negotiated separately through national health technology assessment bodies. Operating across both regimes means maintaining distinct regulatory and pricing strategies for the US and European markets, increasing compliance overhead.

Could This Approach Survive Legal Challenges?

The FDA's authority to grant, modify, or revoke drug approvals is well established. Using that authority specifically to enforce pricing goals, however, is legally untested. Industry trade groups and several legal scholars have questioned whether the executive order exceeds the agency's statutory mandate under the Federal Food, Drug, and Cosmetic Act, which centers on safety and effectiveness — not cost.

Any formal attempt to revoke an approved drug's market authorization solely on pricing grounds would almost certainly face litigation. That prospect alone may give the FDA considerable use: the threat of a protracted legal battle — and the uncertainty it creates for revenue projections — could push manufacturers toward voluntary pricing concessions without the agency needing to follow through on revocation. For BD teams, this means modeling not just the probability of direct FDA action but the secondary effects of regulatory uncertainty on deal timelines and valuations.

Frequently Asked Questions

External Resources for Deeper Insight

For teams building regulatory and BD strategies around this shift:

• FDA Drug Development and Approval Process — the agency's official overview of how drugs are reviewed and approved.
• Most-Favored-Nation Prescription Drug Pricing Executive Order (May 2025) — the full Federal Register text directing FDA action.
• EMA Marketing Authorization Overview — the European framework for context on how pricing and approval are separated in the EU.

Related coverage

• Manufacturing pipeline approvals: what the evidence confirms
• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
• FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx